NHS Improvement, the body that oversees the financial stability, quality, and operational performance of England’s National Health Service (NHS) trusts, reports that switching patients to biosimilars and generics of high-cost drugs led to £324 million ($424 million) in savings in the last financial year, and that it could benefit from an additional £100 million ($131 million) in savings this financial year from greater biosimilar use.
NHS Improvement, the body that oversees the financial stability, quality, and operational performance of England’s National Health Service (NHS) trusts, reported this week that switching patients to biosimilars and generics of high-cost drugs led to £324 million ($424 million) in savings in the last financial year, and that it could benefit from an additional £100 million ($131 million) in savings this financial year from greater biosimilar use.
For the 2017 to 2018 financial year, NHS Improvement set a savings target of £250 million ($327 million) and sought to achieve that goal by switching patients from 10 of the highest-cost therapies to generic or biosimilar alternatives. The NHS beat its goal, due in part to switches to lower-cost biosimilars for infliximab, etanercept, and rituximab.
Switching patients to biosimilars of these drugs led to significant cost savings: infliximab biosimilars delivered £99.4 million in savings, etanercept biosimilars delivered £60.3 million, and rituximab biosimilars delivered £50.4 million, for a cumulative savings equivalent to approximately $275 million in US currency.
This year, the NHS expects to achieve its additional £100 million in savings by taking advantage of biosimilars for 2 more high-cost therapies: trastuzumab, for the treatment of HER2-positive breast cancers, and adalimumab, for the treatment of inflammatory diseases. Biosimilar trastuzumab has been commissioned as an alternative to the reference Herceptin since July 2018, and multiple adalimumab biosimilars are expected to become available in October 2018. The NHS reports that the reference adalimumab, Humira, is the single drug on which the NHS currently spends the most money each year.
Next steps for NHS Improvement include developing a monthly tracking system that will allow individual NHS trusts to assess where they can save money by switching to any of the 10 better value medicines. Discussing the tracker, Member of Parliament Steve Barclay, health minister for the Department of Health and Social Care, said in a statement, “We want to support the NHS to make sure every penny is spent effectively. For too long vital funds have been used to buy expensive medicines instead of equally effective and better value alternatives. Under our long-term plan for the NHS, which will see us increase funding by an average 3.4% per year, we need to do better.”
Additionally, as part of its commissioning framework for biologics, the NHS seeks to ensure that at least 90% of new patients be prescribed the “best value biological medicine,” and that 80% of existing patients be given the best value medicines within a year of a biosimilar’s launch. The frameworks asks providers to keep up to date with local policies on switching to biosimilars, and to ensure that they know what their practices are spending on biologic treatments.
Finally, the NHS also has a recommendation for patients: those receiving treatment with biologics should ask their healthcare providers if there are suitable biosimilar options that they may receive for treatment.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.